SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

September 8, 2020

We are beyond proud to see our portfolio company SpyBiotech take their COVID-19 vaccine to human trials alongside the Serum Institute of India. What a great day for their team, for science, and for the world at large.

SpyBiotech’s unique protein superglue technology could become a powerful new tool in the fight against infectious diseases and cancer. The success of this trial would provide a meaningful indication of that. As their CEO, Sumi Biswas, says, “our technology can be combined with multiple vaccine delivery platforms to create a plug and display vaccine which is critical for generating vaccines rapidly and safely.”

Read SpyBiotech’s full press release here.

Back to News

Stay up to date

Get the latest on cutting edge developments from our enterprises straight to your inbox